Effectiveness and safety of raloxifene in postmenopausal females

Journal of the College of Physicians and Surgeons Pakistan

Volumn 15, Issue 5, 2005, Pages 266-269

  Abdullah, Khalida Nasreen ^c   Raoof, Ali ^a   Raoof, Mustafa ^b  

^a JINNAH SINDH MEDICAL UNIVERSITY   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c Peshawar Cantonment   (Pakistan)

Author keywords

Cholesterol; Endometrium and breast cancer; HDL; LDL; Post menopausal women; Raloxifene; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOT FLUSH; HUMAN; LEG CRAMP; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MAMMOGRAPHY; PAKISTAN; PATIENT COMPLIANCE; POSTMENOPAUSE; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA DISEASE;

BREAST; COHORT STUDIES; ENDOMETRIUM; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 21244475164     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Shaw RW, Soutter WP, Stanton SL. Gynaecology. 2nd edi. Edinburgh. Churchill Livingstone, 1997.
2. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-13.
3. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458-61.
4. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Slampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93.
5. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-29.
6. Yang NN, Venugopatan M, Hardikar S, Glasebook A. Identification of an estrogen response element activated by metabolites of 17β - estradiol and raloxifene. Science 1996; 273: 1222-5.
7. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130: 545-53.
8. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288: 321-33.
9. Delmas PD, Bjarnason NH, Mitlak BH, Huster WJ, Ravoux AC, Shah AS, et al. Effects of reloxifene on bone meneral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337: 1641-7.
10. Barrett, Connor E, Grady D, Sashegyi A, Anderson PW, Eox DA, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women; four year results from the MORE (Multiple Outcome of Raloxifene Evaluation) randomized trial. JAMA 2002, 287: 847-57.
11. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999; 281: 2189-97.
12. Davies GC, Huster WJ, Lu Y, Plouffe L, Laskshmanan M. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999, 93: 558-65.
13. Johnson CC Jr, Bjarnason NH, Coihen FJ, Shah AS, Lindsay R, Mitlak BH, et al. Long-term effects of raloxifene on bone mineral density, bone turnover and serum lipids in early postmenopausal women. 3-year data from two double blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160: 3444-50.
14. Tsai KS, Yen ML, Pan HA, Wu MH, Cheng WC, Hsu SH, et al. Raloxifene versus continuous combined estrogen/progestin therapy : densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 2001, 12: 1020-5.
15. Kung AW, Chao HT, Huang KE, Need AG, Taechakraichana N, Loh FH, et al. Efficacy and safety of raloxifene 60 mg/day in post menopausal Asian women. J Clin Endocrinol Metabol 2003; 88: 3130-36.
16. Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch Jacquotte A. Prospective study of factors influencing the onset of natural menopause. J Clin Epidemiol 1998, 51: 1271-6.
17. Boulet MJ, Oddens B J, Lehert P, Vermer H M, Visser A. Climacteric and menopause in seven South East Asian countries. Maturitas 1994; 19: 157-76.
18. Walsh BW, Kullar LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and caogulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51.
19. Naven P, Lunde T, Benedetti-Panici P, Titinen A, Marinescu B, et al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. BJOG 2003; 110: 157-67.
20. Cohen FJ, Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving Raloxifene or placebo during osteoporosis prevention trials. Maturitas 2000; 34: 65-73.
21. Obermeyer CM. Menopause across cultures: a review of the evidence. Menopause 2000; 7: 737-40.
22. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-40.